Health Affairs September 4, 2019
Joshua T. Cohen, James D. Chambers, Madison C. Silver, Pei-Jung Lin, Peter J. Neumann

Cell and gene therapies have the potential to revolutionize treatment for a range of severe diseases, but their introductions also force difficult economic conversations. This blog post offers three observations to help the community evaluate the costs and benefits of new—and in many cases, extremely costly—therapies.

Expensive Cell And Gene Therapies May Fare Well In Cost-Effectiveness Analyses

Expensive therapies—even those with record high prices—may offer substantial health gains and thus have comparable value, in terms of cost-effectiveness, to less expensive conventional treatments. To assess the extent to which cell and gene therapies offer true breakthrough health benefits, we compared the incremental quality-adjusted life year (QALY) gains associated with cell and gene therapies to corresponding gains for conventional (small molecule)...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Precision Medicine, Pricing / Spending, Provider, Technology
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Understanding the politics of drug pricing in the United States
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
AstraZeneca plans independent drug supply chains for US and China, CEO says
Digital Platforms Streamline Medication Access and Delivery

Share This Article